Published in Thorax on December 08, 2009
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med (2012) 1.80
Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med (2012) 1.46
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 1.01
Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung (2012) 0.98
Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2015) 0.91
Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res (2010) 0.89
Pirfenidone treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag (2011) 0.83
IPF clinical trial design and endpoints. Curr Opin Pulm Med (2014) 0.83
Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther (2014) 0.81
Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J (2011) 0.80
Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care (2011) 0.80
Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung (2015) 0.79
State of the art in the diagnosis and management of interstitial lung disease. Clujul Med (2015) 0.76
Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm Rehabil Prev (2014) 0.76
Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome. Orphanet J Rare Dis (2017) 0.75
Idiopathic pulmonary fibrosis in Saudi Arabia: Demographic, clinical, and survival data from two tertiary care hospitals. Ann Thorac Med (2014) 0.75
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results. Eur Clin Respir J (2016) 0.75
Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res (2017) 0.75
Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. BMC Pulm Med (2017) 0.75
Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med (2017) 0.75
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care (2003) 19.69
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
Spirometric standards for healthy nonsmoking adults. Am Rev Respir Dis (1971) 9.69
Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol (1994) 9.50
Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med (2001) 8.95
The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J (1985) 8.06
Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed) (1982) 7.77
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
A maximal multistage 20-m shuttle run test to predict VO2 max. Eur J Appl Physiol Occup Physiol (1982) 4.64
Effect of encouragement on walking test performance. Thorax (1984) 4.44
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med (2001) 4.39
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes (2003) 3.42
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis (1981) 2.86
Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD (2005) 2.85
Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.71
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual Life Outcomes (2008) 2.07
Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med (2005) 1.86
Reproducibility of walking test results in chronic obstructive airways disease. Thorax (1988) 1.84
Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes (2005) 1.69
Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD (2005) 1.68
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax (2005) 1.64
Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. Respir Med (2009) 1.47
Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology (2008) 1.32
Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study. Intern Med (2007) 1.14
A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax (2001) 1.09
Dyspnoea at 6-min walk test in idiopathic pulmonary fibrosis: comparison with COPD. Respir Med (2006) 0.92
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med (2011) 6.74
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A (2007) 5.95
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88
Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med (2008) 5.82
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Clinical decisions. American Board of Internal Medicine maintenance of certification program. N Engl J Med (2010) 4.85
Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med (2005) 4.25
The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med (2005) 4.25
The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med (2005) 4.15
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation (2013) 3.90
Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2003) 3.89
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Sarcoidosis. Lancet (2003) 3.60
Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest (2006) 3.59
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
Gene expression profiling of familial and sporadic interstitial pneumonia. Am J Respir Crit Care Med (2006) 3.32
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med (2003) 3.00
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med (2004) 2.97
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J (2013) 2.92
Pulmonary fibrosis associated with aluminum trihydrate (Corian) dust. N Engl J Med (2014) 2.88
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol (2013) 2.74
Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med (2007) 2.69
Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med (2007) 2.66
Family asthma management routines: connections to medical adherence and quality of life. J Pediatr (2005) 2.66
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med (2011) 2.62
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J (2012) 2.57
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med (2012) 2.54
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Human pulmonary chimerism after hematopoietic stem cell transplantation. Am J Respir Crit Care Med (2003) 2.50
Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol (2002) 2.43
Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med (2004) 2.42
Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc (2006) 2.40
Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med (2010) 2.40
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.32
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA (2013) 2.20
Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One (2010) 2.19